阿那曲唑联合依维莫司治疗乳腺癌的效果及对血清HER-2/neu、p185水平的影响

目的探究阿那曲唑联合依维莫司用于治疗乳腺癌的临床疗效及其对患者血清中人类表皮生长因子受体2蛋白(HER-2/neu)、p185水平的影响。方法选取2013年1月至2018年12月广元市第一人民医院治疗的符合纳入标准的患者1000例,按照随机数字表法分为对照组(n=500)和观察组(n=500)。对照组给予口服阿那曲唑片,观察组在对照组的基础上给予口服依维莫司片。治疗3个月后,观察比较2组患者的临床疗效及不良反应发生率,比较2组患者雌激素、HER-2/neu、p185水平。结果观察组的临床缓解率为60.60%,要明显高于对照组(54.20%),差异有统计学意义(χ^2=4.190,P=0.041)。治疗前,2组患者的雌二醇(E2)、黄体生成素(LH)、HER-2/neu、p185水平比较,差异无统计学意义(P>0.05)。经过3个月的治疗,观察组的E2、LH、HER-2/neu、p185水平均明显低于对照组(t=8.148,P=0.000;t=85.170,P=0.000;t=20.209,P=0.000;t=16.109,P=0.000)。治疗过程中,对照组和观察组患者不良反应发生率分别为8.60%和7.60%,差异无统计学意义(χ^2=0.340,P=0.562)。结论阿那曲唑联合依维莫司治疗乳腺癌具有良好的临床疗效,可抑制肿瘤细胞的生长发育,降低患者体内雌激素水平,且安全性高。

Effect of anatrizole combined with evimostr on breast cancer and its effect on serum HER-2/neu,p185 level

Objective To explore the clinical efficacy of anastrozole combined with everolimus in the treatment of breast cancer and its effect on the serum levels of human epidermal growth factor receptor-2(HER-2/neu)and p185.Methods From January 2013 to December 2018,1000 patients who met the inclusion criteria were divided into control group(n=500)and observation group(n=500).The control group was given oral anastrozole tablets,and the observation group was given oral everolimus tablets on the basis of the control group.After 3 months of treatment,the clinical efficacy and the incidence of adverse reactions of the two groups were observed and compared,and the levels of estrogen,HER-2/neu and p185 of the two groups were compared.Results The clinical remission rate of the observation group was 60.60%,which was significantly higher than that of the control group(54.20%),the difference was statistically significant(χ^2=4.190,P=0.041).Before treatment,there was no significant difference in estradiol(E2),luteinizing hormone(LH),HER-2/neu and p185 between the two groups(P>0.05).After 3 months of treatment,the levels of E2,LH,HER-2/neu and P185 in the observation group were significantly lower than those in the control group(t=8.148,P=0.000;t=85.170,P=0.000;t=20.209,P=0.000;t=16.109,P=0.000).During the treatment,the incidence of adverse reactions in the control group and the observation group were 8.60%and 7.60%,respectively,with no significant difference(χ^2=0.340,P=0.562).Conclusion The combination of anastrozole and everolimus has a good clinical effect in the treatment of breast cancer.It can inhibit the growth and development of tumor cells,reduce the level of estrogen in patients,and has a high safety.